Scarica l'app Stockscreener
676.23
4.07%
26.42
Pre-mercato:
674.61
-1.62
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$649.81
Aprire:
$663.18
Volume 24 ore:
918.46K
Relative Volume:
0.95
Capitalizzazione di mercato:
$70.90B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
16.48
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+8.45%
1M Prestazione:
+6.42%
6M Prestazione:
-16.75%
1 anno Prestazione:
+25.67%
Intervallo 1D:
$659.02
$677.92
Intervallo di 1 settimana:
$623.89
$677.92
Portata 52W:
$537.45
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
919.94 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Ducks Amgen's Eylea Antitrust Counterclaims - Law360
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron director Arthur Ryan sells $130,030 in stock - Investing.com
Form 4 Regeneron Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Canada
Regeneron director Arthur Ryan sells $130,030 in stock By Investing.com - Investing.com Canada
Regeneron gains as investors look past one-time Q2 charge and focus on pipeline - Quiver Quantitative
REGN Maintained by RBC Capital -- Price Target Lowered to $696 - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Swedbank AB - MarketBeat
Regeneron Pharmaceuticals profile and stock context for US investors - AD HOC NEWS
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $696 - Moomoo
REGN Maintained by Truist Securities -- Price Target Lowered to $769 - GuruFocus
Benchmark Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy - MarketBeat
REGN Upgraded by Benchmark -- Price Target Announced at $185 - GuruFocus
RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $696 From $707, Maintains Sector Perform Rating - marketscreener.com
Regeneron Pharmaceuticals (REGN) Could Be 22% Below Fair Value After Cemdisiran Review Win - simplywall.st
Regeneron Pharma 1Q Adj EPS $9.47 >REGN - Moomoo
Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma - Stocktwits
REGN Maintains Buy Rating with HSBC -- Price Target Lowered to $880 - GuruFocus
FDA to fast-track Regeneron drug facility in Saratoga County - Yahoo Finance
Regeneron Pharmaceuticals, Inc. Files Form 8-K with SEC: Key Company Details and Compliance Information - Minichart
Regeneron Pharmaceuticals (REGN) Anticipates $127M R&D Charge in Q2 2026 - GuruFocus
Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns By Investing.com - Investing.com Canada
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $990 - Moomoo
Regeneron (REGN) warns $127M Q2 IPR&D charge will cut EPS by $1 - Stock Titan
K.J. Harrison & Partners Inc Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN): Investor Outlook With A Strong 27% Potential Upside - DirectorsTalk Interviews
How One Researcher's Personal Study Experience Is Helping Him Better Serve Patients - Clinical Leader
Should Cemdisiran’s Priority Reviews and First-in-Class siRNA Status Require Action From Regeneron (REGN) Investors? - simplywall.st
Regeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiran - Yahoo Finance
Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain - Yahoo Finance
Simplify Asset Management Inc. Has $8.42 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 11,050 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions - simplywall.st
REGNRegeneron Pharmaceuticals Inc Latest SEC Filings - Finviz
Janney Montgomery Scott LLC Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
New data strengthen cemdisiran case in generalized MG - The Pharma Letter
Regeneron Pharmaceuticals (REGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceu - The National Law Review
Regeneron Pharma strengthens its position in biotech. Focus on long-term growth and innovation - AD HOC NEWS
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program - BioSpace
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology
Lansforsakringar Fondforvaltning AB publ Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Element Squared LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
FDA selects seven companies including Eli Lilly and Regeneron for accelerated manufacturing review pilot - grafa.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Benzinga
Regeneron opens the week with analyst focus, shares on NASDAQ radar - AD HOC NEWS
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):